We found that one patient (3.0%) in the RBV+IFN-α-treated group, two patients (5.6%) in the LPV/r+IFN-α-treated group, and two patients (6.3%) in the RBV+LPV/r+IFN-α-treated group had been re-classified as severe cases of COVID-19. The gene discussed is IFNA1; the disease is COVID-19.